Skip to main content

12-09-2022 | ESMO 2022 | Conference coverage | Video

TROPiCS-02 shows sacituzumab govitecan OS benefit in HR+, HER2– advanced breast cancer

Hope Rugo outlines the latest results from the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor-positive, HER2-negative advanced breast cancer and discusses where the antibody–drug conjugate fits into the treatment paradigm (4:42).